Bioactive Peptide Market to surpass US$ 10,149.9 Mn by 2030

Global Bioactive Peptide Market, by Source (Plant, Milk, Eggs, Meat, Fish and Others (Bacterial Antimicrobial Peptides and Venom Peptidomics)), by Therapeutic Area (Antihypertensive, Antioxidant, Immunostimulatory, Antimicrobial, Diabetes, and Others( Gastrointestinal System and Cardiovascular System)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others(Drug Store and Mail-Order Pharmacy)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa), is estimated to be valued at US$ 4,960.4  Million in 2022 and is projected to exhibit a CAGR of 9.4% over the forecast period (2022- 2030).

Bioactive peptides are incorporated in dietary supplements, pharmaceuticals, and novel food supplements. Such formulations tailored with health benefits are used extensively across the globe to optimize health outcomes.

Collagen peptides are now being incorporated into a variety of sports and active nutrition products to improve physical performance of athletes. In March 2019, Gelita, a food company, launched the collagen peptide which can be used in a variety of functional and nutritional beverages. Moreover collagen peptides are easily absorbed by the body and are highly bioavailable which provides better and quick results.

Moreover, in October 2021, Ancient Nutrition, a regenerative agriculture brand company, announced the launch of new line of Collagen Peptides that delivers results in one day to support resilient skin, strong nails and hair, flexible joints, a healthy gut and more.

Global Bioactive Peptide Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus or COVID-19 outbreak started in Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. The economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020.

Increasing use of food derived bioactive peptides as target for mitigating Covid-19 had driven growth of the global bioactive peptide market during the pandemic. For instance, on December 31, 2021, Journal of food bioactive, an open access journal, published a report on Potential target for mitigation of COVID-19 by food-derived bioactive peptides, which reported that oral administration of food protein hydrolysate and naturally occurring peptides exerted beneficial effects beyond conventional nutritional functions by supplying amino acids for protein synthesis, whereas food-derived peptides and amino acid metabolites had been suggested to decrease risk factors of COVID-19 by modulating the renin-angiotensin system, the innate immune system, and the antioxidant system.

Thus, impact of the Coronavirus (COVID-19) pandemic had positive impact on growth of the global bioactive peptide market.         

Global Bioactive Peptide Market: Key Developments

Market players are focused on development of novel products, through partnerships and agreements. For instance, in July 2019, Nuritas, a biotechnology company and Stonehaven Incubate, a Venture Studio, entered a partnership agreement for development of advanced animal health solutions, with an initial focus on animal feed ingredient. Nuritas Ltd. combines artificial intelligence and genomics to discover and unlock natural Bioactive Peptides.

Moreover, increasing number of inorganic strategies such as product launch using Artificial Intelligence (AI) by market players is expected to drive growth of the global bioactive peptide market over the forecast period. For instance, in November 2018, Nuritas, a biotechnology company, announced the commercial launch of PeptAIde, a bioactive ingredient discovered and delivered through artificial intelligence (AI). It is being brought to the market by BASF, a chemical company, which was launched commercially in the U.S. in 2018 with additional launches in Asia Pacific and Europe in 2019.

Browse 36 Market Data Tables and 30 Figures spread through 167 Pages and in-depth TOC on Bioactive Peptide Market, by Source (Plant, Milk, Eggs, Meat, Fish and Others (Bacterial Antimicrobial Peptides and Venom Peptidomics)), by Therapeutic Area (Antihypertensive, Antioxidant, Immunostimulatory, Antimicrobial, Diabetes, and Others( Gastrointestinal System and Cardiovascular System)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others (Drug Store and Mail-Order Pharmacy)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Global Forecast to 2030”

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/bioactive-peptide-market-3018

Key Takeaways of the Global Bioactive Peptide Market:

• Global bioactive peptide market is expected to witness a CAGR of 9.4 % during the forecast period, owing to increasing awareness and reliability on bioactive products offering a strong consumer base for the market. Bioactive ingredients are essential for various health purposes, and to prevent chronic diseases that may occur due to lack of required nutrients in the body.
• Among Source, the plant bioactive peptide segment held a dominant position in the global bioactive peptide market in 2022, owing to rising demand for effective as well as quality products, combined with technological advancements. For instance, on May 9, 2022, according to the reports published in Evidence Based Complementary and Alternative Medicine, a Peer-reviewed journal, reported that bioactive peptides derived from flowers inhibit alpha-glycosidase, alpha-amylase, DPP-IV, and glucose transporter systems which act as an anti-diabetic and decrease blood sugar level.
• Among therapeutic area, the antihypertensive segment held a dominant position in the global bioactive peptide market in 2022, owing to rising prevalence of cardiovascular diseases such as coronary artery disease, congenital heart failure, and angina. For instance, according to the American Heart Association 2021 report, the age-adjusted death rate attributable to cardiovascular disease (CVD), based on 2018 data, was 217.1 per 100,000 in the U.S., whereas on an average, someone dies of CVD every 36 seconds in the U.S. There were 2,380 deaths from CVD each day, based on 2018 data in the U.S.
• Key players operating in the global bioactive peptide market include, Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd., Naturade, Royal DSM, MYOS RENS Technology Inc., Natural Factors Inc., Valio Oy, GenScript, HELIX BIOMEDIX, Oryn Therapeutics, Selecta Biosciences, NIBEC, vivitide, PEPTIDE INSTITUTE, INC, BCN Peptides, Setlance srl., APEPTICO Forschung und Entwicklung GmbH, and BIONANOPLUS.